
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics Inc is advancing its pipeline candidates, notably in high-value indications, which bodes well for future revenue potential. The company's innovative POZ Platform delivery technology addresses existing limitations in drug delivery, enhancing the efficacy of challenging small molecules, particularly in the treatment of neurological diseases and pain. Additionally, the potential clinical success of SER-270 could significantly contribute to long-term financial forecasts, further underscoring the favorable outlook for the company's valuation, especially given the anticipated global acceptance of SER-252.
Bears say
Serina Therapeutics Inc. reported a consistent net loss of $0.64 per share, reflecting ongoing financial challenges for the company. The outlook is further complicated by several risks including potential delays in advancing their lead candidate SER-252 into clinical assessments, difficulties in achieving regulatory approvals, and slower-than-anticipated market uptake due to competitive pressures. Additionally, the company's net loss forecast for 2025 has been significantly revised upward to $2.01 per share from a previous estimate of $0.36, highlighting concerns regarding its financial viability and operational execution.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares